Dr. Jenny C. Chang

Emergency Medicine
281 1st Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
281 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jenny Chang is an Emergency Medicine provider in New York, New York. Dr. Chang is rated as an Experienced provider by MediFind in Tissue Biopsy. Her top areas of expertise are Inappropriate Sinus Tachycardia (IST), Aseptic and Alopecic Nodules of Scalp (AANS), Boils, Gallbladder Disease, and Tissue Biopsy.

Her clinical research consists of co-authoring 153 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Emergency Medicine
Hospital Affiliations
Mount Sinai Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
281 1st Ave, New York, NY 10003

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Multicenter Phase I/Ib Trial of Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer
Multicenter Phase I/Ib Trial of Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: March 11, 2025
Intervention Type: Drug
Study Drugs: Olaparib, Vorinostat
Study Phase: Phase 1
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Enrollment Status: Recruiting
Publish Date: January 27, 2025
Intervention Type: Drug, Radiation
Study Drugs: Letrozole, Palbociclib
Study Phase: Phase 2
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab
Study Phase: Phase 2
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
Multicenter Phase II Trial of Durvalumab (MEDI4736) with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
Multicenter Phase II Trial of Durvalumab (MEDI4736) with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL)
Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL)
Enrollment Status: Suspended
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drugs: Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab, IL-12 gene therapy, L-NMMA
Study Phase: Phase 2
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases
Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Enrollment Status: Terminated
Publish Date: April 14, 2020
Intervention Type: Biological, Procedure, Drug
Study Phase: Phase 2
A Pilot Study: Emotions Immunology and Breast Cancer
A Pilot Study: Emotions Immunology and Breast Cancer
Enrollment Status: Completed
Publish Date: August 28, 2019
Intervention Type: Behavioral, Other
Study Phase: Not Applicable
View 10 Less Clinical Trials

153 Total Publications

Erratum: Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic.
Erratum: Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic.
Journal: JCO oncology practice
Published: March 19, 2025
Similar Doctors
Experienced in Tissue Biopsy
Dr. Noah P. Kondamudi
Emergency Medicine | Pediatrics
Experienced in Tissue Biopsy
Dr. Noah P. Kondamudi
Emergency Medicine | Pediatrics
30 Bergen St, Admc 12 1205, 
Newark, NJ 
 (11.0 miles away)
973-972-0037
Languages Spoken:
English
See accepted insurances

Noah Kondamudi is an Emergency Medicine specialist and a Pediatrics provider in Newark, New Jersey. Dr. Kondamudi is rated as an Experienced provider by MediFind in Tissue Biopsy. His top areas of expertise are Intussusception in Children, Scarlet Fever, Infantile Neutropenia, and Tissue Biopsy.

Experienced in Tissue Biopsy
Dr. Antonio L. Marra
Emergency Medicine
Experienced in Tissue Biopsy
Dr. Antonio L. Marra
Emergency Medicine

Mgm Ketamine Services LLC

690 Kinderkamack Rd, Suite 103, 
Oradell, NJ 
 (16.2 miles away)
201-483-3760
Languages Spoken:
English
See accepted insurances

Antonio Marra is an Emergency Medicine provider in Oradell, New Jersey. Dr. Marra is rated as an Advanced provider by MediFind in Tissue Biopsy. His top areas of expertise are Schizoaffective Disorder, Gallbladder Disease, Folliculitis, Boils, and Tissue Biopsy.

Mark S. Silverberg
Experienced in Tissue Biopsy
Dr. Mark S. Silverberg
Emergency Medicine
Experienced in Tissue Biopsy
Dr. Mark S. Silverberg
Emergency Medicine
445 Lenox Rd, 
Brooklyn, NY 
 (5.7 miles away)
718-245-4790
Languages Spoken:
English
See accepted insurances

Mark Silverberg is an Emergency Medicine provider in Brooklyn, New York. Dr. Silverberg is rated as an Advanced provider by MediFind in Tissue Biopsy. His top areas of expertise are Endoscopy and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chang's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile